Healthlead Public Company Limited

Healthlead Public Company Limited

4.48
THB
0.00
(0.00%)
0.23EPS
24.65P/E
1.42BMarket Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3.33
3.91
5.81
5.59
6.01
7.27
8.3
8.49
Basic EPS, GAAP
0.08
0.19
0.39
0.43
0.27
0.29
0.29
0.23
Free Cash Flow per Basic Share
0.21
0.3
0.34
0.06
0.03
0.04
0.6
0.36
Dividend per Share
- -
0.2
0.18
0.16
0.18
0.15
0.17
0.22
Book Value per Share
0.4
0.52
3.18
3.46
3.56
3.7
3.58
3.46
Tangible Book Value per Share
0.37
0.43
3.09
3.38
3.47
3.6
3.49
3.36
Basic Weighted Avg Shares
272
272
206
272
272
272
268
262
Sales/Revenue/Turnover
906
1,064
1,199
1,520
1,636
1,977
2,229
2,223
Operating Margin (%)
3.56
6.9
8.56
9.77
6.16
4.82
4.96
4.02
Depreciation Expense
13
25
31
38
56
77
93
98
Net Income, GAAP
22
52
80
118
75
78
78
59
Effective Tax Rate (%)
24.23
21.73
18.16
17.23
20.58
18.86
20.95
20.17
Profit Margin (%)
2.4
4.89
6.65
7.78
4.57
3.96
3.49
2.67
Working Capital
20
19
743
703
649
643
644
571
LT Debt
16
101
102
148
199
260
274
245
Total Equity
108
141
866
942
968
1,006
968
878
Return on Invested Capital (%)
- -
24.32
12.98
11.6
6.88
6.58
6.7
5.81
Return on Capital (%)
- -
25.73
13.27
11.75
7.11
7.16
7.03
6.01
Return on Common Equity (%)
- -
41.88
15.83
13.08
7.82
7.93
7.89
6.44

Capital Structure

THB

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
45
46
47
LT Borrowings
- -
- -
- -
LT Finance Leases
274
275
245
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
270
256
254
Market Capitalization
1,946
1,577
1,423

Working Capital

THB

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
913
945
815
Cash, Cash Equivalents & STI
549
531
411
Accounts Receivable, Net
6
7
7
Inventories
309
370
358
Total Current Liabilities
269
312
244
Payables & Accruals
221
263
194
ST Debt
45
46
47
Deferred Revenue
- -
- -
- -

Growth Rates

THB

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
105.51%
-3.8%
Free Cash Flow
- -
268.16%
1,456.48%
Net Income, GAAP
- -
13.77%
-0.52%
Sales/Revenue/Turnover
- -
16.13%
12.73%
Total Cash Common Dividend
- -
-1.49%
13.33%

Quarterly Revenue

THB

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
482
465
503
527
1,977
2025
570
548
546
565
2,229
2026
585
527
- -
- -
- -

Quarterly Earnings Per Share

THB

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
0.04
0.06
0.11
0.29
2025
0.08
0.06
0.05
0.1
0.29
2026
0.07
- -
- -
- -
- -

Quarterly Dividends Per Share

THB

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.15
- -
- -
0.15
2025
- -
0.17
- -
- -
0.17
2026
- -
0.22
- -
- -
- -

Company Description

CEO
Supakorn Bhandhukanonda
Full Time Employees
120
Sector
Finance
Industry
Financial conglomerates
Address
99/4, Moo 10 Bang-Yai NU Thailand 11140
IPO Date
Dec 3, 2021
Business
Healthlead Public Company Limited is a holding company that invests in and operates pharmacy retail and healthcare product development businesses in Thailand. Through subsidiaries including Icare Health and Healthiness, the company distributes medicines, medical supplies, cosmeceuticals, dietary supplements such as those under the PRIME and Besuto brands, medical equipment, and other healthcare products across more than 10,000 stock-keeping units; it also develops innovative preventive healthcare solutions in collaboration with external researchers and manufacturers, alongside brands like iCare, Pharmax, vitaminclub, and Super Drug for pharmaceuticals, disinfectants, deodorizers, and masks. Founded in 2018 and headquartered in Bang Yai, Nonthaburi, Thailand, Healthlead operates a network of approximately 28 pharmacy branches primarily in Thailand, with ambitions to expand across the ASEAN Economic Community. In 2025, the company continues an active share repurchase program for financial management purposes, completing a tranche in May acquiring 8.55 million shares or 3.17% of its capital for THB 57.79 million and ongoing purchases through November including 3.03 million shares since October. As of mid-2025, it reports steady performance with total revenues and net profit growth highlighted in its first half results, alongside routine financial disclosures for the second quarter ending June 30.